Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development fo...

Full description

Bibliographic Details
Main Authors: Monica Giovannini, Vanesa Gregorc, Carmen Belli, Elisa Roca, Chiara Lazzari, Maria Grazia Viganò, Anna Serafico, Eugenio Villa
Format: Article
Language:English
Published: Hindawi Limited 2009-01-01
Series:Journal of Oncology
Online Access:http://dx.doi.org/10.1155/2009/849051

Similar Items